Exact Sciences Announces Preliminary Fourth Quarter 2020 Results
- Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M
News provided by
Share this article
Share this article
MADISON, Wis., Jan. 10, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $464.5 million and $467.5 million for the fourth quarter ended Dec. 31, 2020. I m incredibly proud of how the Exact Sciences team came together during 2020 to make progress towards our mission of eradicating cancer and the suffering it causes, said Kevin Conroy, chairman and CEO of Exact Sciences. Following our combination with Thrive, we are confident in making blood-based, multi-cancer screening a reality and being a leading provider of earlier, smarter cancer tests for patients at every step of their journey. We ve never been more excited abo
Share this article
Share this article
MADISON, Wis., Dec. 28, 2020 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conference and invited investors to participate by webcast.
J.P. Morgan Healthcare Conference
Presentation followed by a Q&A session on Wednesday, January 13, 2021 at 2:50 p.m. EST
The webcast can be accessed in the investor relations section of Exact Sciences website at www.exactsciences.com.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit th
New Data at SABCS 2020 Highlight the Role of the Oncotype DX Breast Recurrence Score® Test in Shaping Clinical Practice
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with node-positive disease
- New meta-analysis of data from more than 10,000 patients with node-negative disease, including the results of TAILORx, supports the Oncotype DX Breast Recurrence Score® test as the standard of care genomic test in early-stage, invasive breast cancer
News provided by
Share this article
MADISON, Wis., Dec. 11, 2020 /PRNewswire/